Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HGR4113 in Healthy Subjects
NCT05642377Phase 1Recruiting
- Sponsor
- Glaceum
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HGR4113 in type 2 diabetes mellitus (T2DM), sponsored by Glaceum. Primary endpoints: Safety and Tolerability Assessment by Adverse Event Monitoring, Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination and 12 more. Started Nov 2022; status: recruiting.
02
Drugs
HGR4113
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05642377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642377.